Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies
R1979-HM-1333
Phase 1 other active
Quick answer
Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies for B-cell non-Hodgkin lymphoma (NHL) is a Phase 1 program (other) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Lacuna Pharma Pty Ltd
- Indication
- B-cell non-Hodgkin lymphoma (NHL)
- Phase
- Phase 1
- Modality
- other
- Status
- active